Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15149262 | 0.76 | HSD11B1 (0.40) | HSD11B1THRBCYP2C9CHRNB2CHRNB4 | |
| SCHEMBL30599114 | 0.75 | EPHX1 (0.31) | — | |
| SCHEMBL29483238 | 0.75 | CHRNB2 (0.33) | KDM4ECHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL699442 | 0.74 | SMN1; SMN2 (0.46) | HSD11B1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1237978 | 0.74 | HSD11B1 (0.39) | HSD11B1KDM4EALDH1A1 | |
| SCHEMBL1236481 | 0.74 | HSD11B1 (0.35) | HSD11B1 | |
| SCHEMBL17331177 | 0.73 | HSD11B1 (0.40) | HSD11B1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| Adamantane SCHEMBL3723679 | 0.73 | ALDH1A1 (0.50) | HSD11B1THRBCYP2C9KDM4ENPC1 | |
| SCHEMBL30599102 | 0.72 | EPHX1 (0.33) | ALDH1A1 | |
| SCHEMBL31719598 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9301950-B2 | Adamantane analogs | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-04-05 | — | — | US | claimed |
| US-20120270917-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-10-25 | — | — | US | claimed |
| WO-2011022191-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-02-24 | — | — | WO | claimed |
| US-9301950-B2 | Adamantane analogs | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-04-05 | — | — | US | disclosed |
| US-20120270917-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2011022191-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270917-A1 | ADAMANTANE ANALOGS | HAVCR2, ADORA2A, ADORA1 | HSD11B1 3481/4885THRB 582/4885CYP2C9 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.